Anadys has A-site in mind

Having recently moved into preclinical development with leads from its Ribosome A-site program, Anadys Pharmaceuticals Inc. is on the verge of validating its RNA targeting capabilities - an important inflection point considering 40% of its R&D efforts are focused on RNA targets.

Despite its involvement in many biological processes, RNA has only recently been considered a drug target because of technical difficulties regarding the preparation, handling and structural analysis of RNA. However, as these hurdles have lessened, there has been an increasing push towards targeting RNA with small molecules...